文献速递妇科肿瘤

SOLO1:新诊断BRCA突变晚期卵巢癌维持奥拉帕利对患者报告结局的影响

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2021-04-13

SOLO1是一项随机双盲3期试验,比较新诊断BRCA突变晚期卵巢癌铂类化疗后维持奥拉帕利与安慰剂。

要点

  • 维持奥拉帕利未对健康相关生活质量产生不利影响。
  • 奥拉帕利显著改善质量调整无进展生存期。
  • 奥拉帕利显著延长无显著毒性症状时间。

核心结论

  • 维持奥拉帕利在显著延长无进展生存期的同时未损害患者健康相关生活质量。
  • 质量调整无进展生存期和无显著毒性症状时间的获益支持奥拉帕利的临床价值。

研究设计与样本

  • 随机、双盲、国际3期试验,在118个中心、15个国家进行。
  • 纳入391例新诊断晚期高级别浆液性或子宫内膜样卵巢癌、原发性腹膜癌或输卵管癌伴BRCA突变且对铂类化疗临床完全或部分缓解的患者。
  • 按2:1随机分配至奥拉帕利300mg每日两次(n=260)或安慰剂(n=131),治疗最长2年。
  • 主要HRQOL终点为前24个月FACT-O TOI评分自基线的变化,TOI评分范围0-100,临床有意义差异定义为至少10分。

关键数值与推荐

  • HRQOL终点在全部随机分配患者中分析。

临床怎么用

  • 对于新诊断BRCA突变晚期卵巢癌铂类化疗后缓解的患者,维持奥拉帕利可在不损害生活质量的前提下显著延长质量调整无进展生存期。
  • 奥拉帕利显著延长无显著毒性症状时间,支持其作为维持治疗的选择。

局限性

  • HRQOL为次要终点,探索性终点需谨慎解读。
  • 试验仍在进行但已停止入组新患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase 3 SOLO1 trial, maintenance olaparib provided a significant progression-free survival benefit versus placebo in patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation in response after platinum-based chemotherapy. We analysed health-related quality of life (HRQOL) and patient-centred outcomes in SOLO1, and the effect of radiological disease progression on health status. METHODS: SOLO1 is a randomised, double-blind, international trial done in 118 centres and 15 countries. Eligible patients were aged 18 years or older; had an Eastern Cooperative Oncology Group performance status score of 0-1; had newly diagnosed, advanced, high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer with a BRCA mutation; and were in clinical complete or partial response to platinum-based chemotherapy. Patients were randomly assigned (2:1) to either 300 mg olaparib tablets or placebo twice per day using an interactive voice and web response system and were treated for up to 2 years. Treatment assignment was masked for patients and for clinicians giving the interventions, and those collecting and analysing the data. Randomisation was stratified by response to platinum-based chemotherapy (clinical complete or partial response). HRQOL was a secondary endpoint and the prespecified primary HRQOL endpoint was the change from baseline in the Functional Assessment of Cancer Therapy-Ovarian Cancer Trial Outcome Index (TOI) score for the first 24 months. TOI scores range from 0 to 100 (higher scores indicated better HRQOL), with a clinically meaningful difference defined as a difference of at least 10 points. Prespecified exploratory endpoints were quality-adjusted progression-free survival and time without significant symptoms of toxicity (TWiST). HRQOL endpoints were analysed in all randomly assigned patients. The trial is ongoing but closed to new participants. This trial is registered with ClinicalTrials.gov, NCT01844986. FINDINGS: Between Sept 3, 2013, and March 6, 2015, 1084 patients were enrolled. 693 patients were ineligible, leaving 391 eligible patients who were randomly assigned to olaparib (n=260) or placebo (n=131; one placebo patient withdrew before receiving any study treatment), with a median duration of follow-up of 40·7 months (IQR 34·9-42·9) for olaparib and 41·2 months (32·2-41·6) for placebo. There was no clinically meaningful change in TOI score at 24 months within or between the olaparib and placebo groups (adjusted mean change in score from baseline over 24 months was 0·30 points [95% CI -0·72 to 1·32] in the olaparib group vs 3·30 points [1·84 to 4·76] in the placebo group; between-group difference of -3·00, 95% CI -4·78 to -1·22; p=0·0010). Mean quality-adjusted progression-free survival (olaparib 29·75 months [95% CI 28·20-31·63] vs placebo 17·58 [15·05-20·18]; difference 12·17 months [95% CI 9·07-15·11], p<0·0001) and the mean duration of TWiST (olaparib 33·15 months [95% CI 30·82-35·49] vs placebo 20·24 months [17·36-23·11]; difference 12·92 months [95% CI 9·30-16·54]; p<0·0001) were significantly longer with olaparib than with placebo. INTERPRETATION: The substantial progression-free survival benefit provided by maintenance olaparib in the newly diagnosed setting was achieved with no detrimental effect on patients' HRQOL and was supported by clinically meaningful quality-adjusted progression-free survival and TWiST benefits with maintenance olaparib versus placebo. FUNDING: AstraZeneca and Merck Sharp & Dohme.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Friedlander M, Moore KN, Colombo N, et al. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 2021. PMID: 33862001. doi:10.1016/S1470-2045(21)00098-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。